BioVaxys Technology Corp. announced that possibly based on the selected study design, results from The Ohio State University (Ohio State) animal study, its collaborator on the development of BioVaxys' pan-sarbecovirus vaccine, did not demonstrate that immunization of study animals with BVX-1021, followed by administration of a SARS-CoV-2 vaccine - in this case with BVX-0320, the Company's Covid-19 vaccine candidate - would stimulate development of neutralizing antibodies to a broad range of sarbecoviruses. The Company previously demonstrated that BVX-0320 stimulated a strong antibody and T cell response in a murine model, and believes that administering BVX-1021 and BVX-0320 is a valid approach for inducing immunity to sarbecoviruses.

The results from the Ohio State animal study showed an excellent emerging tolerability profile for BVX-1021, with no observed side effects or noteworthy clinical observations.